Skip to main content
. 2011 Nov;72(5):745–757. doi: 10.1111/j.1365-2125.2011.04026.x

Table 2.

Summary of clinical studies

Study Description Treatment Mortality Comments
Addo & Poon-King [84] Uncontrolled 72 patients CP, Dex, MP, vitamin B, vitamin C 28% No follow-up after discharge. Plasma paraquat measured in only 25 patients. Of the patients who had concentrations over 2 mg l−1, only 6/18 survived
Afzali & Gholyaf [87] RCT 20 patients CP, Dex, MP vs. conventional treatment 33% vs. 81% Plasma paraquat not measured. Sample size and power calculation not performed, no follow-up after discharge
Perriens et al. [89] Uncontrolled 47 patients CP, Dex vs. conventional treatment 63% vs. 61% Exposure confirmed
Lin et al. [86] RCT 23 patients CP, Dex, MP vs. conventional treatment 31% vs. 86% Power calculation not done. No follow-up after discharge
Lin et al. [80] RCT 50 patients CP, Dex, MP vs. conventional treatment 68% vs. 82% 71 patients were excluded from post hoc analysis. Plasma paraquat not measured. No follow-up after discharge
Lin et al. [85] 16 patients 17 historic controls CP, Dex, MP 25% vs. 70% Exposure unconfirmed. Used historic controls. No follow-up after discharge
Yasaka et al. [28] Uncontrolled 9 patients Vitamin E 100–4000 mg day−1 78%
Hong et al. [99] Uncontrolled 5 patients Vitamin C escalating doses 0%

CP, cyclophosphamide; Dex, dexamethasone; MP, methylprednisolone; DFO, desferroxamine.